PMID- 33335139
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20210510
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Dec 17
TI  - A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behcet's 
      syndrome.
PG  - 22227
LID - 10.1038/s41598-020-78718-z [doi]
LID - 22227
AB  - Infliximab (IFX) was the first biologic introduced for refractory uveitis 
      treatment in Behcet's syndrome (BS). However, there have been few reports on the 
      safety and efficacy of IFX monotherapy over follow-up periods of more than 
      10 years. This retrospective study evaluated the 10-year safety and efficacy of 
      IFX monotherapy compared to IFX combination therapies with colchicine or 
      corticosteroid for refractory uveitis in BS patients. Monotherapy was performed 
      in 30 eyes of 16 patients while combination therapies were performed in 20 eyes 
      of 11 patients. Continuation of IFX occurred in 70.3% of enrolled patients for 
      10 years without any significant difference noted in the retention rate between 
      the monotherapy and combination therapies (p = 0.86). Reduction of ocular 
      inflammatory attacks and improvement of best corrected visual acuity occurred in 
      the monotherapy group after 10 years, which was equivalent to that for the 
      combination therapies. Although adverse events (AEs) or therapy discontinuation 
      occurred during the initial 5 years in both therapies, no AEs were observed for 
      either therapy after 6 years. Our results suggested that IFX monotherapy proved 
      to be effective and not inferior to combination therapies over a 10-year 
      follow-up. Although loss of response and AEs may be noticed during the initial 
      5-year period, a safe and effective continuation can be expected thereafter.
FAU - Horiguchi, Noe
AU  - Horiguchi N
AD  - Department of Ophthalmology & Visual Science, Graduate School of Medical and 
      Dental Sciences, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, 
      Bunkyo-ku, Tokyo, 113-8519, Japan.
AD  - Department of Ophthalmology, Nagano Prefectural Federation of Agricultural 
      Cooperatives for Health and Welfare, Saku General Hospital, Nagano, Japan.
FAU - Kamoi, Koju
AU  - Kamoi K
AD  - Department of Ophthalmology & Visual Science, Graduate School of Medical and 
      Dental Sciences, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, 
      Bunkyo-ku, Tokyo, 113-8519, Japan. koju.oph@tmd.ac.jp.
FAU - Horie, Shintaro
AU  - Horie S
AD  - Department of Ophthalmology & Visual Science, Graduate School of Medical and 
      Dental Sciences, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, 
      Bunkyo-ku, Tokyo, 113-8519, Japan.
FAU - Iwasaki, Yuko
AU  - Iwasaki Y
AD  - Department of Ophthalmology & Visual Science, Graduate School of Medical and 
      Dental Sciences, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, 
      Bunkyo-ku, Tokyo, 113-8519, Japan.
FAU - Kurozumi-Karube, Hisako
AU  - Kurozumi-Karube H
AD  - Department of Ophthalmology & Visual Science, Graduate School of Medical and 
      Dental Sciences, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, 
      Bunkyo-ku, Tokyo, 113-8519, Japan.
FAU - Takase, Hiroshi
AU  - Takase H
AD  - Department of Ophthalmology & Visual Science, Graduate School of Medical and 
      Dental Sciences, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, 
      Bunkyo-ku, Tokyo, 113-8519, Japan.
FAU - Ohno-Matsui, Kyoko
AU  - Ohno-Matsui K
AD  - Department of Ophthalmology & Visual Science, Graduate School of Medical and 
      Dental Sciences, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, 
      Bunkyo-ku, Tokyo, 113-8519, Japan.
LA  - eng
PT  - Journal Article
DEP - 20201217
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Immunosuppressive Agents)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antirheumatic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Behcet Syndrome/diagnosis/*drug therapy
MH  - Drug Resistance
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunosuppressive Agents/administration & dosage/adverse effects/therapeutic use
MH  - Infliximab/administration & dosage/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - Retreatment
MH  - Symptom Assessment
MH  - Treatment Outcome
MH  - Uveitis/diagnosis/*drug therapy
MH  - Visual Acuity
PMC - PMC7747559
COIS- The authors declare no competing interests.
EDAT- 2020/12/19 06:00
MHDA- 2021/05/11 06:00
PMCR- 2020/12/17
CRDT- 2020/12/18 05:43
PHST- 2020/09/15 00:00 [received]
PHST- 2020/11/27 00:00 [accepted]
PHST- 2020/12/18 05:43 [entrez]
PHST- 2020/12/19 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
PHST- 2020/12/17 00:00 [pmc-release]
AID - 10.1038/s41598-020-78718-z [pii]
AID - 78718 [pii]
AID - 10.1038/s41598-020-78718-z [doi]
PST - epublish
SO  - Sci Rep. 2020 Dec 17;10(1):22227. doi: 10.1038/s41598-020-78718-z.